MedTrace Logo

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

NCT04668521 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 215

Last updated 2023-12-26

No results posted yet for this study

Summary

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

Conditions

  • Adnexal Mass
  • Germline BRCA1 Gene Mutation
  • Germline BRCA2 Gene Mutation
  • Hereditary Breast and Ovarian Cancer

Interventions

OTHER

OVA360

Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection

Sponsors & Collaborators

  • Aspira Women's Health

    lead INDUSTRY

Principal Investigators

  • Todd Pappas, PhD · Aspira Women's Health

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-04
Primary Completion
2023-12-15
Completion
2023-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04668521 on ClinicalTrials.gov